Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR‑NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catamaran Bio, Inc., a biotechnology company developing off‑the-shelf NK cell therapies to treat cancer, today announced that the company will present preclinical efficacy data for its allogeneic, cryopreserved CAR-NK cell therapies designed to treat solid tumors, engineered using Catamaran’s TAILWIND^TM platform. The data demonstrate the promise of two of the company’s CAR-NK cell therapies, CAT-248 and CAT-179, for the treatment of solid tumors, and will be presented in two poster presentations at the Society for Immunotherapy in Cancer (SITC) 37^th Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022.

Details of the poster presentations are as follows:

Title for CAT-248 poster: Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies

• Lead Authors: Branden Moriarity, PhD, Associate Professor, Division of Hematology/ Oncology and Jae-Woong Chang, PhD, Research Associate, University of Minnesota (research agreement sponsored by Catamaran Bio); Eugene Choi, Principal Scientist, Catamaran Bio
• Session Date and Time: November 11, 2022, 9:00 a.m. – 8:30 p.m.
• Location: Poster Hall
• Abstract Number: 392

Title for CAT-179 poster: Allogeneic natural killer cells engineered to express HER2-directed CAR, interleukin-15 and TGFß dominant negative receptor effectively control HER2+ tumors

• Lead Author: Finola Moore, PhD, Director, Catamaran Bio
• Session Date and Time: November 11, 2022, 9:00 a.m. – 8:30 p.m.
• Location: Poster Hall
• Abstract Number: 264

Both abstracts will become available online on the SITC conference website beginning at 8:00 a.m. ET on Monday, November 7, 2022.

About Catamaran Bio

Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWIND™ platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures, Astellas Venture Management, and the UMN Discovery Capital investment program. For more information, please visit www.catamaranbio.com and follow us on LinkedIn and @CatamaranBio on Twitter.

Contacts

Catamaran contact:

Mark Boshar, Chief Operating Officer

617-620-9709

[email protected]

Media Contact:

Kathryn Morris, The Yates Network

914-204-6412

[email protected]